

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

RELTON *et al.*

Appl. No.: 10/587,714

§ 371 Date: June 4, 2007

For: **Treatment of Conditions Involving
Dopaminergic Neuronal
Degeneration Using Nogo Receptor
Antagonists**

Confirmation No.: 2306

Art Unit: 1647

Examiner: Sandra L. WEGERT

Atty. Docket: 2681.0450001/SAC/JBF

Reply to Requirement For Election of Species

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Sir:

In reply to the Office Action dated May 6, 2009, Applicants hereby provisionally elect:

(1) SEQ ID NO:3 as a species of NgR1 (claims 1-6, 10-12, and 19-23 are readable thereon),

(2) Parkinson's disease as a disease or disorder (claims 1-6 and 10-23 are readable thereon),

(3) HB 7E11 as a monoclonal antibody (claims 1-4, 13-16, and 19-23 are readable thereon), and

(4) SEQ ID NO:17 as an antigen (claims 1-4 and 13-23 are readable thereon).


These elections are made without traverse, and without prejudice to or disclaimer of the other claims or inventions disclosed. In accordance with 37 C.F.R. § 1.141(a), with respect to the species elections made, Applicants reserve the right to claim

additional species, and/or to have additional species searched and/or examined, in the event that a generic claim is found to be allowable.

It is believed that extensions of time are not required, beyond those that may otherwise be provided for in accompanying documents. However, in the event that additional extensions of time are necessary to prevent abandonment of this application, then such extensions of time are hereby petitioned under 37 C.F.R. § 1.136(a), and any fees required therefor are hereby authorized to be charged to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Shannon A. Carroll, Ph.D.
Attorney for Applicants
Registration No. 58,240

Date: July 6, 2007

1100 New York Avenue, N.W.
Washington, D.C. 20005-3934
(202) 371-2600

984422_1.DOC